Journal
PHYTOMEDICINE
Volume 94, Issue -, Pages -Publisher
ELSEVIER GMBH
DOI: 10.1016/j.phymed.2021.153810
Keywords
Gegen qinlian decoction; Type 2 diabetes osteoporosis; IGFBP3/MAPK/NFATc1 signaling pathway; Cytokine antibody array
Categories
Funding
- National Natural Science Foundation of China [81774339, 82074462]
- Major research project of Guangzhou University of Chinese Medicine [XK2019012]
- Guang-dong Science Province and Technology Program Project [2017A020213030]
- Guangzhou Science and Technology Planning Project [201707010319]
Ask authors/readers for more resources
Experimental studies have shown that GQD has a protective effect in managing T2DOP by upregulating IGFBP3 expression and downregulating the IGFBP3/MAPK/NFATc1 signaling pathway.
Background: Osteoporosis affects more than half the patients with type 2 diabetes mellitus (T2DM). Up to data, there is no effective clinical practice in managing type 2 diabetes osteoporosis (T2DOP) because of its complex pathogenesis. Gegen Qinlian Decoction (GQD) has been used for the long-term management of T2DM. However, the underlying mechanism of GQD in the treatment of T2DOP remains unknown. Purpose: To reveal the role of GQD in T2DOP and its potential therapeutic targets in the management of T2DOP. Study Design: The effect of GQD on T2DOP was observed in db/db mice in four groups: model group, GQD lowdose group (GQD-L), GQD high-dose group (GQD-H), and metformin (positive control) group. C57BL/6J mice were used as the negative control group. Methods: Quantitative phytochemical analysis of GQD was performed using high-performance liquid chromatography (HPLC). Micro-CT and hematoxylin-eosin (H&E) staining were used to evaluate bone histomorphometry. To screen for candidate targets of GQD, a cytokine antibody array was used, followed by bioinformatics analysis. Quantitative real-time PCR (qRT-PCR) and western blotting (WB) were used to determine expression levels. Results: The major active components of GQD were confirmed by HPLC. Micro-CT and H&E staining showed that bone mass was significantly increased in the GQD-H group compared with the model group. Antibody arrays revealed that the expression of insulin-like growth factor binding protein 3 (IGFBP3) was elevated in the GQD-H group. The MAPK pathway was identified using bioinformatics analysis. Additionally, the levels of osteoclastogenesis-related genes, including cathepsin K (Ctsk), acid phosphatase 5 (Acp5), matrix metallopeptidase 9 (Mmp9), and ATPase H+ transporting VO subunit D2 (Atp6vOd2) were significantly decreased in the GQD-H group. Compared with the model group, high-dosage GQD inhibited phosphorylation of extracellular signal-regulated kinases (ERKs) and P38 mitogen-activated protein kinase (MAPK) and the expression of c-Fos and nuclear factor of activated T cells 1 (NFATc1). Conclusion: GQD plays a protective role in T2DOP by upregulating IGFBP3 expression and downregulating the IGFBP3/MAPK/NFATc1 signaling pathway. IGFBP3 in serum may also be a novel biomarker in the treatment of T2DOP. Our current findings not only expand the application of GQD, but also provide a theoretical basis and guidance for T2DOP.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available